Evaluation of the SAMe-TT2R2 score to predict the quality of anticoagulation control in a cohort of patients with venous thromboembolism treated with vitamin K antagonists

详细信息    查看全文

• 作者：Pablo Demelo-Rodrí ; guez^a ; ^{pbdemelo@hotmail.com" class="auth_mail" title="E-mail the corresponding author} ; Andrea Postigo-Esteban^b ; Irene Garcí ; a-Ferná ; ndez-Bravo^a ; Martí ; n Agud^a ; Silvia Calpena^a ; Mario Camacho^a ; Jorge del Toro-Cervera^a
• 关键词：Acenocoumarol ; Warfarin ; venous thromboembolism ; International normalized ratio ; Anticoagulants
• 刊名：Thrombosis Research
• 出版年：2016
• 出版时间：November 2016
• 年：2016
• 卷：147
• 期：Complete
• 页码：58-60
• 全文大小：210 K

文摘

The SAMe-TT₂R₂ score has been recently proposed to predict the quality of anticoagulation control in patients with atrial fibrillation treated with vitamin K antagonists (VKA). We aimed at calculating this score in a cohort of patients with Venous Thromboembolism (VTE) and determine its usefulness.

Methods

We included all consecutive patients with VTE treated with VKA for > 90 days. We collected all variables included in the score (female sex, age < 60 years, medical history [> 2 comorbidities], treatment [interacting drugs: e.g. amiodarone], tobacco [doubled], race [doubled]) and analyzed the relationship between the SAMe-TT₂R₂ score and time in therapeutic range (TTR), determined by the Rosendaal method and by the percentage of INR determinations (after excluding the first month).

Results

135 patients were treated with VKA for > 90 days, with a median TTR 65%. No differences in INR controls within range were found between patients with score 0–1 vs ≥ 2 (64.7 ± 19.5% vs 66.0 ± 20.5%, p = 0.728). No differences were found in INR controls above (21.5 ± 18.1% vs 21.2 ± 21.3%, p = 0.605) or below (3.9 ± 14% vs 2.9 ± 15.9%, p = 0.517) the therapeutic range.

Conclusion

The SAMe-TT₂R₂ score is not useful to predict quality of anticoagulation control in patients with VTE treated with VKA.